These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8930053)

  • 1. Depot neuroleptic usage in adults with learning disabilities.
    Gravestock S
    J Intellect Disabil Res; 1996 Feb; 40 ( Pt 1)():17-23. PubMed ID: 8930053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Results of a survey on the use of delayed-action neuroleptics in psychiatry].
    Bourin M; Venisse JL; Lecuyer F
    Encephale; 1990; 16(5):363-9. PubMed ID: 1979942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The subjective experiences of people who regularly receive depot neuroleptic medication in the community.
    Phillips L; McCann E
    J Psychiatr Ment Health Nurs; 2007 Sep; 14(6):578-86. PubMed ID: 17718731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications.
    Hägg S; Joelsson L; Mjörndal T; Spigset O; Oja G; Dahlqvist R
    J Clin Psychiatry; 1998 Jun; 59(6):294-9. PubMed ID: 9671341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depot neuroleptic therapy: an underutilized treatment option.
    Glazer WM; Kane JM
    J Clin Psychiatry; 1992 Dec; 53(12):426-33. PubMed ID: 1362569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmaceutical characteristics of depot neuroleptics. Their use and efficacy in the psychiatric clinic].
    Mungiu OC; Chiriţă V; Boişteanu P; Mungiu A; Cosmovici N; Pirozynski T
    Rev Med Chir Soc Med Nat Iasi; 1988; 92(1):43-7. PubMed ID: 2899341
    [No Abstract]   [Full Text] [Related]  

  • 7. Neuroleptic malignant syndrome in 12 of 9,792 Chinese inpatients exposed to neuroleptics: a prospective study.
    Deng MZ; Chen GQ; Phillips MR
    Am J Psychiatry; 1990 Sep; 147(9):1149-55. PubMed ID: 1974744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches.
    Ereshefsky L; Saklad SR; Jann MW; Davis CM; Richards A; Seidel DR
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):50-9. PubMed ID: 6143748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depot flupenthixol decanoate for schizophrenia or other similar psychotic disorders.
    Quraishi S; David A
    Cochrane Database Syst Rev; 2000; (2):CD001470. PubMed ID: 10796442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tardive dyskinesia in outpatients on depot phenothiazine.
    Neehall J
    West Indian Med J; 1989 Dec; 38(4):228-33. PubMed ID: 2576166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective.
    Dencker SJ
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):22-7. PubMed ID: 6143744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Demographic predictors of the use of injectable versus oral antipsychotic medications in outpatients.
    Price N; Glazer W; Morgenstern H
    Am J Psychiatry; 1985 Dec; 142(12):1491-2. PubMed ID: 2866719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Community treatment orders: relationship to clinical care, medication compliance, behavioural disturbance and readmission.
    Vaughan K; McConaghy N; Wolf C; Myhr C; Black T
    Aust N Z J Psychiatry; 2000 Oct; 34(5):801-8. PubMed ID: 11037366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Depot preparations in psychiatry].
    Gunby B
    Tidsskr Nor Laegeforen; 1974 Jan; 94(3):176-7. PubMed ID: 4150719
    [No Abstract]   [Full Text] [Related]  

  • 15. Monitoring and documentation of side effects from depot antipsychotic medication: an interdisciplinary audit of practice in a regional mental health service.
    Cleary A; Walsh F; Connolly H; Hays V; Oluwole B; Macken E; Dowling M
    J Psychiatr Ment Health Nurs; 2012 Jun; 19(5):395-401. PubMed ID: 22070791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt?
    Bloch Y; Mendlovic S; Strupinsky S; Altshuler A; Fennig S; Ratzoni G
    J Clin Psychiatry; 2001 Nov; 62(11):855-9. PubMed ID: 11775044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of age on the pharmacological management of ambulatory patients treated with depot neuroleptic medications for schizophrenia and related psychotic disorders.
    Mamo DC; Sweet RA; Chengappa KN; Reddy RR; Jeste DV
    Int J Geriatr Psychiatry; 2002 Nov; 17(11):1012-7. PubMed ID: 12404650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Social aspects of therapy with depot neuroleptics in the Federal Republic of Germany.
    Haring C; Tegeler J; Lehmann E; Ptock WD
    Acta Psychiatr Belg; 1981; 81(2):189-202. PubMed ID: 6117189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A versatile new sustained-action neuroleptic: pipotiazine palmitate in psychiatric practice.
    Johnston RE; Niesink F
    J Int Med Res; 1979; 7(3):187-93. PubMed ID: 37133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naturalistic, retrospective comparison between second-generation antipsychotics and depot neuroleptics in patients affected by schizophrenia.
    Marchiaro L; Rocca P; LeNoci F; Longo P; Montemagni C; Rigazzi C; Bogetto F
    J Clin Psychiatry; 2005 Nov; 66(11):1423-31. PubMed ID: 16420080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.